Alto Neuroscience is a clinical-stage biotechnology company developing biology-driven medicines for neuropsychiatric conditions. The company aims to make psychiatric treatment more precise by using insights into individuals’ brain biology to predict clinical response and identify patients most likely to benefit from its drug candidates. This approach is intended to move beyond the trial-and-error methods commonly used in treating these conditions and help patients get better faster.

Drawing on 15 years of neurobiology research, Alto develops medicines designed to target core brain processes. Its initial focus is on major depressive disorder, bipolar depression, and schizophrenia. The company’s work combines neurobiological research with expertise in central nervous system drug development and commercialization, with the goal of providing alternative treatment options for people living with these conditions.

Alto shares information about its scientific platform, publications, and clinical pipeline, as well as company and investor updates. Headquartered in Mountain View, California, the company is working to advance precision approaches in psychiatry and improve the development and delivery of treatments for patients.